Scarica l'app Stockscreener
66.60
0.46%
-0.31
Dopo l'orario di chiusura:
66.68
0.08
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$66.91
Aprire:
$67.78
Volume 24 ore:
5.12M
Relative Volume:
0.93
Capitalizzazione di mercato:
$206.53B
Reddito:
$51.21B
Utile/perdita netta:
$6.50B
Rapporto P/E:
31.94
EPS:
2.085
Flusso di cassa netto:
$6.76B
1 W Prestazione:
-0.61%
1M Prestazione:
-0.86%
6M Prestazione:
-16.50%
1 anno Prestazione:
+0.53%
Intervallo 1D:
$66.59
$67.78
Intervallo di 1 settimana:
$64.22
$67.78
Portata 52W:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
66.60 | 206.53B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman - GlobeNewswire Inc.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Yahoo Finance
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo - News & Insights
2025-01-20 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - PR Newswire
AstraZeneca gets first US approval for cancer treatment Datroway - ShareCast
AstraZeneca Plc Datroway approved in the US for metastatic breast cancer - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Oak Ridge Investments LLC - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
Professional Advisory Services Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Position Cut by Boston Common Asset Management LLC - MarketBeat
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector (NASDAQ:AZN) - Seeking Alpha
Procyon Advisors LLC Has $2.21 Million Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
23,847 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Empirical Asset Management LLC - MarketBeat
US FDA approves AstraZeneca's drug for breast cancer - Reuters.com
AstraZeneca, Daiichi Win FDA Approval for Breast Cancer Drug - Bloomberg
2025-01-17 | Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline - Benzinga
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
AstraZeneca rises Friday, still underperforms market - MarketWatch
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - Benzinga
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
AstraZeneca changes management of its China unit (AZN:NASDAQ) - Seeking Alpha
Faruqi & Faruqi Reminds AstraZeneca Investors of the - GlobeNewswire
AstraZeneca lymphoma drug gets expanded U.S. approval (AZN) - Seeking Alpha
AstraZeneca overhauls management of its China division, FT reports -January 17, 2025 at 09:12 am EST - Marketscreener.com
AstraZeneca overhauls management of its scandal-hit China division - Financial Times
Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Calquence Wins FDA Approval for Mantle Cell Lymphoma - TipRanks
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - Investing.com
Ritholtz Wealth Management Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA grants full approval for AstraZeneca's Calquence - The Pharma Letter
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Pharmaceutical Technology
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
AstraZeneca drug for rare blood cancer gets US regulatory green light - Proactive Investors USA
AstraZeneca: Calquence approved for LCM by the FDA -January 17, 2025 at 03:00 am EST - Marketscreener.com
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FDA approves AstraZeneca's Calquence for untreated mantle cell lymphoma By Investing.com - Investing.com UK
AstraZeneca's rare cancer drug Calquence gets US regulatory nod - ShareCast
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action - PR Newswire
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca rises Thursday, outperforms market - MarketWatch
Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class ActionAZN - Morningstar
Park Avenue Securities LLC Has $5.07 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Pines Wealth Management LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Assenagon Asset Management S.A. Has $55.65 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):